Skip to main content

Day: January 25, 2026

FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review

Written by Customer Service on . Posted in Public Companies.

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA action date set for May 24, 2026 TOKYO and CAMBRIDGE, Mass., Jan. 25, 2026 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai’s Supplemental Biologics License Application (sBLA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector (SC-AI), LEQEMBI IQLIK, as a weekly starting dose. LEQEMBI is indicated for the treatment of Alzheimer’s disease (AD) in patients with Mild Cognitive...

Continue reading

Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies

Written by Customer Service on . Posted in Public Companies.

First surgeon-reported case using RECELL®, PermeaDerm®, and Cohealyx™ together in a single care pathwayNew clinical and tissue-level data on PermeaDerm and Cohealyx highlight wound bed preparation and readiness for closureRECELL analyses show consistent trends in healing, reduced complications, and shorter hospital stays across studies and real-world registry dataVALENCIA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) — AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced data from 19 scientific abstracts, including 14 podium presentations, at the 2026 Boswick Burn & Wound Symposium. The presentations include the first surgeon-reported integrated use of all three AVITA Medical technologies – RECELL, PermeaDerm, and Cohealyx...

Continue reading

Baker Hughes Announces Fourth-Quarter and Full-Year 2025 Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Fourth-quarter highlightsOrders of $7.9 billion, including $4.0 billion of IET orders. Record RPO of $35.9 billion, including record IET RPO of $32.4 billion. Revenue of $7.4 billion, flat year-over-year. Attributable net income of $876 million. GAAP diluted EPS of $0.88 and adjusted diluted EPS* of $0.78. Adjusted EBITDA* of $1,337 million, up 2% year-over-year. Cash flows from operating activities of $1,662 million and free cash flow* of $1,341 million.Full-year highlightsOrders of $29.6 billion, including record $14.9 billion of IET orders. Revenue of $27.7 billion, flat year-over-year. Attributable net income of $2,588 million. GAAP diluted EPS of $2.60 and adjusted diluted EPS* of $2.60. Adjusted EBITDA* of $4,825 million, up 5% year-over-year. Cash flows from operating activities of $3,810 million and free cash flow* of $2,732...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.